Rare Diseases

All Conditions

Thymic Epithelial Tumor

single arm for all patients tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.

blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.

* tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.
* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.

single arm for all patients

Clémence BASSE, MD

Clémence Basse, MD

Agathe SEGUIN, MD

Agathe SEGUIN

Edouard SAGE, MD

The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).

In this prospective study, patients undergoing thymectomy and thymomectomy as part of routine care undergo the following care pathway:

1. During the pre-surgical visit (for n = 50 patients): as part of routine care, a blood sample is collected for analysis of CBC, leukocytes, lymphocytes, CRP, ferritinemia, TSH, T3L, T4L, anti-acetycholine receptor antibodies, ...CMV, EBV, HSV, HIV serologies, ...and HLA class I and class II typing.
2. During thymectomy and thymomectomy surgery, the following samples are taken (for n = 50 patients):

   * 6 blood samples on EDTA tubes are collected at the time of surgery for analyses.
   * 3 fresh samples of the surgical specimen are taken by the pathologist: tumour T, juxta-tumour J and distant D locations for analyses by flow cytometry and RNA sequencing. Anatomopathology blocks/slides are also cut in the same way (tumour T, juxta-tumour J and distant D locations) for additional exploratory analyses.
   * The feasibility of developing patient-derived xenografts (PDX) from TETs will be tested for n = 20 tumor samples. These models will allow to test potential therapeutic agents for this pathology.
3. During the 1st month (+/- 7 days) post-surgery check-up, a blood sample is taken again (for n = 50 patients) for routine care: CBC, leukocytes, lymphocytes, CRP, ferritinemia, anti-acetycholine receptor antibodies and for peripheral immune system analysis at a distance from surgery and for constitutional molecular analysis.

Informed consent is given to participate in this prospective study.

Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)

Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

description of genetic abnormalities in thymic tumours compared to non-tumourous thymic tissue (Whole Exome Sequencing RNA-sequencing technique, DNA Optical mapping);

description of immune cells in the tumour environment, description of tumour infiltrating T cells

Molecular constitutional characterisation of TETs with the technique of theExome Sequencing (WES) on blood samples of patients with TETs

WES data analysis constitutional genetic alterations will be performed.

Molecular analyses will be performed to identify potential alterations in signalling pathways that can be targeted by new therapies.

Analysis of TETs single-cell RNA-seq data will be performed.

Transcriptome sequencing analysis will be performed.

Epigenetic characterisation of TETs will be performed by molecular analyses.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)	NCT05558644	Cancer	single arm for ...	18 Years -	Institut Curie
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)	NCT05558644	Cancer	single arm for ...	18 Years -	Institut Curie

Spots Global Cancer Trial Database for single arm for all patients